Establishment of a novel therapeutic method for multiple sclerosis via plasmablasts

Research Project

Project/Area Number	26860262
Research Category	Grant-in-Aid for Young Scientists (B)
Allocation Type	Multi-year Fund
Research Field	Experimental pathology
Research Institution	Osaka University
Principal Investigator	Matsumoto Masanori 大阪大学, 免疫学フロンティア研究センター, 特任助教 (50542106)
Project Period (FY)	2014-04-01 – 2016-03-31
Project Status	Completed (Fiscal Year 2015)
Budget Amount *help	¥3,900,000 (Direct Cost: ¥3,000,000、Indirect Cost: ¥900,000) Fiscal Year 2015: ¥1,560,000 (Direct Cost: ¥1,200,000、Indirect Cost: ¥360,000) Fiscal Year 2014: ¥2,340,000 (Direct Cost: ¥1,800,000、Indirect Cost: ¥540,000)
Keywords	多発性硬化症 / IL-10 / plasmablast / plasmablasts / 脳脊髄炎
Outline of Final Research Achievements	B cells can suppress experimental autoimmune encephalomyelitis, a mouse model of multiple sclerosis, by secreting an anti-inflammatory cytokine, IL-10. However, whether human plasmablasts can also serve as predominant IL-10 producers remains unknown. By culturing peripheral blood B cells derived from healthy donors in vitro, we found that plasmablasts predominantly produced IL-10 and that their IL-10 production was mediated by activation of IRF4 and NFAT. Thus, these results suggest that human plasmablasts can serve as IL-10 producers to suppress multiple sclerosis.

Report

(3 results)